According to filings with the U.S. Securities and Exchange Commission, SPR Therapeutics is raising up to $25,641,473.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Maria Bennett played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SPR Therapeutics
SPR Therapeutics, Inc. is a privately-held medical device company committed to improving the lives of millions of pain sufferers with its peripheral nerve stimulation (PNS) platform technology poised to be the standard of care and ultimately, the treatment of choice for pain management. Led by a world-class team of scientists, physicians, and business professionals with a track record of commercializing innovative neurostimulation products, SPRs PNS therapy for acute and chronic pain management provides a non-narcotic, reversible, safe, effective and more affordable alternative to addictive opioid medications and invasive surgeries. We are focused on developing, manufacturing and commercializing non-opioid, minimally invasive, treatment options that improve quality of life. And, our SPRINT technology is the only percutaneous Peripheral Nerve Stimulation (PNS) System cleared to treat both chronic and acute pain.

To learn more about SPR Therapeutics, visit http://www.sprintpns.com/

Contact:
Maria Bennett, President and Chief Executive Officer
216-378-9108
https://www.linkedin.com/in/maria-bennett-75909511/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.